Inhibition with DBZ resulted in abated JAG1 expression in mDLL4-tumours compared to that of mDLL4-tumour control (V versus II) while bevacizumab had no significant effects on JAG1 expression in all three types of tumours compared to that of all control tumours (VII-IX versus I-III). This evidence concerns the gene ZNF365 and neoplasm.